Konopleva et al 1 describe the expression of Bcl-2 in 2 acute myeloid leukemia (AML) cell lines, HL-60 and HL-60-doxorubicin-resistant, and in fresh AML cells obtained from patients with newly diagnosed or recurrent AML. The focus of their study was to investigate the effect of liposomal Bcl-2 antisense oligonucleotides (Bcl-2-ASs) on proliferation and chemotherapy sensitivity of these AML cells. Indeed, the authors report convincingly that Bcl-2-ASs reduce Bcl-2 protein levels and increase cytosine-arabinoside cytotoxicity in both HL-60 cell lines and in 11 of 19 primary AML samples.
Response:
Human A1 expression in acute myeloid leukemia
We thank Drs Moreb and Zucali for their comments on our report concerning the effects of Bcl-2 antisense oligonucleotides (Bcl-2-ASs) on proliferation, apoptosis, and sensitivity to Ara-C in primary acute myeloid leukemia (AML) and myeloid leukemia cell lines. 1 We further stated that apoptosis was induced by Bcl-2-ASs although other antiapoptotic proteins were Northern analysis for human A1 mRNA expression. WT U937 cells or U937 cells transfected with pLSXN retroviral vector or pLXSN containing Bcl-2 in the sense orientation were exposed to 1 g/mL bleomycin, which induces myeloid differentiation in these cells (increased granularity and CD11b expression), and assayed for the expression of A1 mRNA. Approximately 20 g total RNA was loaded in each lane. IL-1-treated A549 lung carcinoma cell line was included (lane 1) for positive control. Other experimental groups included WT U937 cells that were either untreated or treated with bleomycin for 2 and 5 days (lanes 2, 3, and 4, respectively); U937 cells expressing Bcl-2 that were either untreated or treated with bleomycin for 2 and 5 days (lanes 5, 6, and 7, respectively); and vector-transfected U937 cells that were either untreated or treated with bleomycin for 2 and 5 days (lanes 8, 9, and 10, respectively). Northern blot was hybridized to a randomly primed 32 P-labeled A1 cDNA. Autoradiograph was developed after 6 days exposure to x-ray film using 2 intensifying screens at Ϫ 80°. Photograph of the corresponding ethidium bromide-stained gel is shown below the autoradiograph for loading control.
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While Drs Moreb and Zucali agree with these findings, they find the data on one of the antiapoptotic proteins, A1, "less convincing." The Bcl-2 family member A1/Bfl-1 was cloned by Choi et al 2 and by Karsan et al. 3 It was found to be expressed in bone marrow cells and is induced by cytokines and differentiation inducers in leukemic cells. 4 Drs Moreb and Zucali state that they "used mainly Northern blot analysis because of the unavailability of a human A1 antibody." The A1 antibody used in our study was kindly provided by Dr John C. Reed. It generated immunoblots of better quality than those obtained with the polyclonal antibody marketed by Santa Cruz. But a paper has recently been published utilizing the Santa Cruz antibody successfully. 5 We here provide our own method of A1 detection:
Cells were washed twice with phosphate buffered saline (PBS) buffer and lysed at 4 ϫ 10 4 cells/L in cell lysis buffer (20 mM Hepes, pH 7.4, 0.25% NP-40 containing protease inhibitor cocktail; Boehringer Mannheim, Indianapolis, IN) for 10 minutes on ice. Lysates were spun at 25 000g for 10 minutes, and an equal amount of 2 ϫ gel-loading buffer (0.25 M Tris-HCl, 2% SDS, 4% ␤-mercaptoethanol, 10% glycerol, 0.02% bromophenol blue) was added to the supernatants. Equal amounts of lysate (equivalent to 5 ϫ 10 5 cells) were subjected to sodium-dodecyl-sulfate polyacrylamide-gel electrophoresis (SDS-PAGE) onto 12% polyacrylamide gels. Afterward, proteins were transferred to Hybond-P membranes (Amersham Pharmacia Biotech, Buckinghamshire, England). The membranes were blocked overnight at 4°C with 7% milk in PBS buffer containing 0.3% Tween-20, followed by incubation with polyclonal antibody against A1 (1:1000 dilution) (kindly provided by Dr J. C. Reed) for 1 hour at room temperature. Membranes were washed 3 times with PBS buffer containing 0.3% Tween-20, probed with a horseradish peroxydase (HRP)-conjugated secondary antibody and then reacted with enhanced chemiluminescence (ECL) reagent (Amersham Pharmacia Biotech). Signals were detected by a phosphoimager (Storm 860 Version 4.0; Molecular Dynamics, Sunnyvale, CA).
Using this method, the A1 bands are clearly discernible at the correct location, and these results are supported by the detection of A1 mRNA by reverse-transcriptase polymerase chain reaction (RT-PCR) in primary AML samples (Figure 1 ). Oligonucleotide primers (F, forward; R, reverse) used for expression analysis by RT-PCR were as follows: human A1-F 5Ј-CGGCATCATTAACT-GGGGAAG-3Ј and R 5Ј-GATCTTTCCTGTAACTTCTAG-3Ј; the expected PCR product is 250 base pairs (bp). Other pro-and antiapoptotic genes are also expressed. In a series of 135 AML analyzed for expression of A1 by semiquantitative RT-PCR, no correlation with white blood cell count or bone marrow blast count was observed.
In conclusion, we have demonstrated the presence of the antiapoptosis protein A1 in primary AML samples by RT-PCR and immunoblot analyses. We agree with Drs Moreb and Zucali that the nature of the interaction between Bcl-2 and other antiapoptotic proteins remains unknown. 
